Skip to main content

Genject

Genject, one of the five syringe manufacturers in Türkiye, operates in its state-of-the-art syringe manufacturing facility in Ankara, covering an area of 18,000 square meters. 

Share Ratio (%): 96,40

Elixir

Elixir conducts R&D activities to develop new and generic drug products and manufacturing processes in compliance with European Medicines Agency (EMA) and United States Food and Drug Administration (US FDA) standards. 

Share Ratio (%): 85,00

Gen Pharma Caucasus Manufacturing Operations MMC

Gen Pharma Caucasus Manufacturing Operations MMC, established through a partnership between GEN, Azerbaijan State Investment Company (AIC), and SIA Pharmaceutical LLC, will build and operate Azerbaijan’s first pharmaceutical manufacturing facility. 

Share Ratio (%): 66,00

Stimusil Inc. 

Stimusil Inc. is a medical device company developing new technologies for safer and more effective photobiomodulation therapy. The company’s goal is to provide solutions for multiple indications in dermatology and aesthetics. 

Share Ratio (%): 16,80

Neo Auvra

Neo Auvra is a local startup company that produces cyber-physical systems and technologies for digital holistic health, digital medicine, and digital therapeutics. 

Pay Oranı (%): 12,39

RS Research

RS Research has developed Türkiye’s first new drug candidate. Through development steps conducted in Türkiye and clinical research to reach patients, this candidate can target different types of cancer using carrier platform technology.

Share Ratio (%): 11,70

h2o therapeutics

Founded in 2014, h2o operates in the field of digital health software. H2O has also established a company named H2O Therapeutics to continue its activities and enhance its presence in the United States. 

Share Ratio (%): 10,00

Galventa AG

Galventa, a Swiss startup, designs clinically proven supplement products using innovative and patented platform technologies. 

 Share Ratio (%): 4,79

InvIOs Holding AG

InvIOs Holding AG is a company focused on discovering and developing next-generation cancer treatments. 

 Share Ratio (%): 0,60